Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025.
加拿大不列顛哥倫比亞省溫哥華和波士頓，2025年1月7日（環球新聞）-- Xenon製藥公司（納斯達克：XENE），一家專注於神經科學的生物製藥公司，致力於爲需要的患者發現、開發和提供改變生活的治療方案，今天宣佈公司將在2025年1月13日至16日在加利福尼亞州舊金山舉行的第43屆J.P.摩根醫療保健會議上進行演講。
Company Presentation Details:
公司演講詳情：
|
Date: |
Monday, January 13, 2025 |
|
Time: |
9:45-10:25 AM Pacific Time (12:45-1:25 PM Eastern Time) |
|
Webcast: |
Register here |
| Presenter: | Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals |
| 日期： |
2025年1月13日，星期一 |
| 時間： |
太平洋時間上午9:45-10:25（東部時間下午12:45-1:25） |
| 網絡廣播： |
在這裏註冊 |
| 演講者： | 伊恩·莫提默，Xenon製藥總裁兼首席執行官 |
A live audio webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
公司演示的現場音頻網絡廣播將在Xenon網站的「投資者」部分提供，並在活動結束後發佈以供重播。上述列出的日期和時間可能會有所變動。
About Xenon Pharmaceuticals Inc.
關於Xenon製藥公司。
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit .
Xenon製藥（納斯達克：XENE）是一家專注於神經科學的生物製藥公司，致力於發現、開發和提供改變生命的治療方案。我們正在推進一個離子通道產品組合，以解決高未滿足醫療需求的領域，包括癲癇和抑鬱症。Azetukalner是一種新型、高效、選擇性的Kv7鉀通道激活劑，代表着在多個適應症的後期臨牀開發中，最先進的、經過臨牀驗證的鉀通道調節劑。欲了解更多信息，請訪問 .
"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
"Xenon"及其Xenon標誌是Xenon製藥公司在多個司法管轄區註冊的商標或商號。所有其他商標均歸各自所有者所有。
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
聯繫方式：
針對投資者：
查德·富傑
副總裁，投資者關係
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
媒體聯繫：
科琳·阿拉披索
高級副總裁，企業事務
(617) 671-9238
media@xenon-pharma.com
